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Conclusion: The obtained sequences may be target genes
transactivated by PS1TP2 protein among which some
genes coding proteins involved in cell cycle regulation,
metabolism, immunity and cell apoptosis. This ﬁnding
brought some clues for studying the biological functions
of PS1TP2.
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Introduction: Primary liver cancer accounts for only
1 2% of malignant tumors found at autopsy in western
countries. However, in some parts of Africa and Asia it
may account for up to 20 30% of all types of malignancy.
The high frequency of HBsAg positivity in individuals with
Hepatocellular Carcinoma (HCC) strongly suggests that
chronic HBV infection may contribute in some way towards
the development of 1ry liver cell carcinoma. Although HCC is
probably caused by one or more environmental carcinogens,
a hereditary predisposition to the tumor has not been
excluded.
Aim: Determine the incidence of HBsAg carriers patients
suffering from primary HCC and detect the association
between primary HCC and HLA.
Subjects and Methods: The material consisted of twenty
patients diagnosed as HCC based on Ultrasonographic ex-
amination and by Histopathology. Laboratory investigations;
liver biopsy, HBsAg, Anti-HBcAg (IgM) and HLA typing using
lymphocyte microcytotoxicity technique.
Results: The 20 studied cases were negative for HBcAb IgM
and 10 patients were positive for HBsAg. HLA typing revealed
signiﬁcant rise of HLA-A9, HLA-B5 among HCC patients. HLA-
A9 was signiﬁcantly increased in HBsAg positive and negative
cases. HLA-B5 was signiﬁcantly increased in HBsAg positive
cases only while HLA-B8 was signiﬁcantly increased in HBsAg
negative cases only.
In cases with mixed hepatic cirrhosis and Schistosomal
hepatic ﬁbrosis which were negative for HBsAg showed
signiﬁcant increase in HLA-A9.
Conclusions:
1. Signiﬁcant association of HBsAg positivity in patients
with HCC.
2. Signiﬁcant association of HLA-A9 and HLA-B5 with HCC.
3. HLA-A9 in patients mixed cirrhosis and Schistosomal
hepatic ﬁbrosis may be predisposing to HCC.
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RNAi is a potential tool for antiviral therapy. However,
plasmid-based shRNA and chemically synthetic siRNA are
ineffective in treating viral infection due to limited
transfection efﬁciency and short half-life. Thus, non-
replicating recombinant viral vectors, in particular lentiviral
DNA which can integrate into host genome, may represent
effective means in antiviral treatment. In order to study
the kinetics of gene silencing, it is desirable to suppress
genes in a regulated fashion. Such regulated RNAi system
can provide a way to express shRNA only when needed or
only in certain cells. Traditional anti-HBV drugs, such as
nucleoside analogues and interferon-a, are only partially
effective in reducing viral loads.
Here we applied the regulated lentiviral delivery system
to investigate the suppressive effect of siRNA on HBV.
We compared two expression systems, a DNA-based vector
(pSuper) under H1 promoter and the lentiviral vector, to
deliver siRNA targeting the direct repeat 1 (DR1) region,
the core promoter (CP) region or the reverse transcriptase
(RT) of HBV genome. First, we designed and constructed
shRNA into the pSuper vector and assessed the effect on
HBV replication in HepG2.2.15 cells. We found that the
shRNA targeting DR1 region (1826nt-1845nt) or the CP region
(1775nt-1795nt) signiﬁcantly suppressed HBV replication,
while shRNA targeting RT only had moderate effect. We
subsequently cloned shRNA cassettes targeting DR1 region
and CP region into the lentiviral vector, respectively.
Recombinant lentiviruses were transduced into HepG2.2.15
cells with 95% efﬁcacy as evidenced by ﬂuorescence
microscopy, resulting in great reduction at both mRNA
and protein levels which were maintained to 96h post-
transduction.
We are currently constructing the tetracycline operator
system into the lentiviral vector to generate a tetracycline
based-regulated RNAi system. This conditional RNAi system
will provide a promising tool to analyze siRNA-mediated
anti-HBV therapy.
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Aim: To explore the prevalence of transfusion transmitted
virus (TTV) infection in patients with viral liver diseases.
Methods: TTV DNA in serum from all enrolled patients with
viral liver disease (VLD) was detected with PCR method.
Anti-HAV, HBV-marker, anti-HCV, anti-HDV and anti-HEV
markers were also tested by ELISA. HBVDNA, HCVRNA and
HGV RNA were detected by PCR and RT-PCR method.
Results: The prevalence rate of TTV infection in VLD
patients was 14.7% (43/292). Of all the patients,
the percentage of TTV infection was 5.0% (2/40),
15.9% (29/182), 31.6% (6/19) and 11.8% (6/51), respectively
in patients with acute hepatitis (AH), chronic hepatitis (CH),
severe hepatitis (SH) and liver cirrhosis (LC); in which the
rate of TTV infection with SH predominated (p < 0.001).
Of all the 43 patients with positive TTV in serum,
5 (11.6%) cases were infected with TTV alone, 38 (88.4%)
patients were super-infected with more than one hepatitis
virus (HV). The double infection rate was signiﬁcantly higher
than the single infection rate (p < 0.01). In the group
infected with TTV, there were 2 AH cases (4.7%), 29 CH
cases (67.4%), 6 SH cases (14.0%) and 6 LC cases (14.0%), and
in which CH predominated (p < 0.01). In AH group, 2 cases
infected with TTV, 1 with TTV only, another one was super-
infected with other HV. In CH group (29), 3 with TTV single
infection, 26 with TTV super-infection. In SH group, 1 was
with TTV single infection, 5 with TTV super-infected. In
LC group, all patients were TTV super-infected. In the group
infected with TTV only, most patients had the symptoms of
CH (60%). In the group super-infected with HV, most patients
were super-infected with HBV (89.5%, 34/38). The super-
infection group was composed of AH, CH, SH and LC (2.6%,
68.4%, 13.2%, and 15.8% respectively).
Conclusions: TTV infection is common in patients with viral
liver disease. TTV is frequently super-infected with other
